United Therapeutics Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.6%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
$26.27next fiscal year
Monitoring Framework
Key Performance Indicators
Tyvaso Franchise Revenue Quarterly457.5MTarget: Return to sequential quarterly growth
Orenitram Quarterly Revenue Quarterly136MTarget: Sustained double-digit year-over-year growth
Annual Peak Revenue Target Annually3.2BTarget: Exceeding 8 billion annually by 2027
Watch Items
- Ralinepag NDA SubmissionTrigger: Submission to the FDAAction: Monitor regulatory timeline in the second half of 2026
- Tyvaso sNDA for Idiopathic Pulmonary Fibrosis (IPF)Trigger: Priority review filingAction: Track submission progress targeted by the end of summer 2026
- Xenotransplantation Clinical TrialsTrigger: Enrollment milestones in 10-gene xenokidney trialAction: Evaluate patient enrollment and subsequent FDA discussions
Research as of 2 Sep 2026